ANAPTYSBIO INC (ANAB)
US0327241065 - Common Stock
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Anaptys Announces Participation in November and December Investor Conferences
Anaptys Announces Participation in November and December Investor Conferences
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for...
Noteworthy Thursday Option Activity: ANAB, ASTS, CWK
Notable Monday Option Activity: ANAB, AIR, FTI
Anaptys Announces Participation in September Investor Conferences
Anaptys Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative...
Why AnaptysBio Was Such a Healthy Stock This Week
The company's immediate future looks promising, as it has a drug that should get a clinical readout within months and a deep-pocketed pharmaceutical peer as an investor.
Noteworthy Wednesday Option Activity: TPR, AMRK, ANAB
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis.
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Led by long-standing investor EcoR1 Capital with participation from additional existing and new investors, including Sanofi...
ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024
ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AnaptysBio (NASDAQ:ANAB) just reported results for the second quarter of 2024.A...
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA...
ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024
ANAB stock results show that AnaptysBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
ANAB Stock Earnings: AnaptysBio Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AnaptysBio (NASDAQ:ANAB) just reported results for the first quarter of 2024.An...
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by...
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous...
Actym Therapeutics Appoints Thomas Smart as CEO
/PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive...
AnaptysBio Breaks Below 200-Day Moving Average - Notable for ANAB
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Wall Street stock predictions can run wild but after the tech sector's gains, these stocks could be better places for your money.
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
A powerfully bullish new analyst take on the company helped it rally on the market.